Last Updated: November 9, 2026

Details for Patent: 11,542,239

Name: Drug Patent Intelligence for US Patent 11542239
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

« Back to Dashboard

Which drugs does patent 11,542,239 protect, and when does it expire?

Patent 11,542,239 protects ORIAHNN (COPACKAGED) and ORILISSA and is included in two NDAs.

This patent has ten patent family members in eight countries.

Summary for Patent: 11,542,239

Title:	Elagolix sodium compositions and processes
Abstract:	The present invention relates to compositions of elagolix sodium, and process and intermediates for the preparation thereof.
Inventor(s):	Niharika Chauhan, Raimundo HO, Albert Kruger, Samrat MUKHERJEE, Stephen T. Chau, Erika Crane, Alex Fabian, Sanjay Chemburkar, Travis Dunn
Assignee:	AbbVie Inc
Application Number:	US16/519,443
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 11,542,239
Patent Claim Types: see list of patent claims	Composition; Compound; Process;

Drugs Protected by US Patent 11,542,239

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Abbvie	ORIAHNN (COPACKAGED)	elagolix sodium,estradiol,norethindrone acetate; elagolix sodium	CAPSULE;ORAL	213388-001	May 29, 2020		RX	Yes	Yes	11,542,239	⤷ Start Trial	Y	Y			⤷ Start Trial
Abbvie	ORILISSA	elagolix sodium	TABLET;ORAL	210450-001	Jul 23, 2018		RX	Yes	No	11,542,239	⤷ Start Trial	Y	Y			⤷ Start Trial
Abbvie	ORILISSA	elagolix sodium	TABLET;ORAL	210450-002	Jul 23, 2018		RX	Yes	Yes	11,542,239	⤷ Start Trial	Y	Y			⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 11,542,239

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2019309706	⤷ Start Trial
Brazil	112021000973	⤷ Start Trial
Canada	3104902	⤷ Start Trial
China	112469417	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.